Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback